# US 2001/0034054 A1 · Materials and methods for simplified AAV production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0034054 A1
- Document ID: US20010034054A1
- Status: Published application
- Kind: A1
- Application number: 09/841,768
- Filed: 2001-04-24
- Published: 2001-10-25
- Earliest claimed: 1997-07-31
- Inventors: Varavani Dwarki; Martha Baillie Ladner; Jaime Escobedo; Shang-Zhen Zhou
- Web page: https://patentgrep.com/patent/US20010034054A1

## CPC

- C12N 15/86: Viral vectors
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14162: by genetic engineering
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides a method for producing purified replication-defective recombinant AAV virions. The method comprises introducing into a suitable host cell an AAV vector, an AAV helper construct and an adenoplasmid accessory construct into the host cell. The adenoplasmid accessory plasmid is composed adenovirus plasmid DNA unable to be packaged into adenoviral particles because it lacks packaging signal sequence(s) or it contains additional sequences making it too large to package. The host cell is cultured to produce crude rAAV virions and then lysed. The resulting cell lysate is applied to a chromatographic column containing sulfonated cellulose or subjected to cesium chloride equilibrium gradient centrifugation and the purified rAAV virions are recovered.

## Claims

### Claim 1

A method for producing replication-defective recombinant AAV virions substantially free of wild-type AAV and helper adenovirus, comprising:
a. introducing into a suitable host cell (i) an AAV vector that is free of AAV coding sequences and that comprises a heterologous gene operatively positioned between two AAV ITRs, (ii) an AAV helper construct having at least one gene encoding an AAV capsid protein, and (iii) an adenoplasmid accessory construct having a full adenoviral genome that either lacks a packaging signal or that contains sufficient additional nucleotides to be rendered unpackagable, to produce a transformed host cell;
b. culturing the transformed host cell to produce replication-defective recombinant AAV virions having said heterologous gene; and
c. lysing the cultured host cell to obtain said replication-defective recombinant AAV virions substantially free of wild-type AAV and adenovirus particles.

### Claim 2 (depends on 1)

The method of claim 1, wherein the adenoplasmid accessory construct has a full adenoviral genome that lacks a packaging signal.

### Claim 3 (depends on 1)

The method of claim 1, wherein the adenoplasmid accessory construct having a full adenoviral genome that contains sufficient additional nucleotides to be rendered unpackagable.

### Claim 4 (depends on 1)

The method of claim 1, wherein the heterologous gene encodes a human protein.

### Claim 5 (depends on 4)

The method of claim 4, wherein said human protein is erythropoietin, thrombopoietin (G-CSF), Factor VIII, Factor IX, Factor Xa, human growth hormone, leptin or IL-2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the adenoplasmid accessory construct is pJM17, pBHG10 or pBHG11.

### Claim 7 (depends on 1)

The method of claim 1 further comprising the steps of:
d. applying the lysate of step (c) to a column comprising sulfonated cellulose; and
e. recovering purified replication-defective recombinant AAV virions substantially free of host cell proteins and host cell debris.

### Claim 8 (depends on 2)

The method of claim 2, wherein the heterologous gene encodes a human protein.

### Claim 9 (depends on 8)

The method of claim 8, wherein said human protein is erythropoietin, thrombopoietin (G-CSF), Factor VIII, Factor IX, Factor Xa, human growth hormone, leptin or IL-2.

### Claim 10 (depends on 2)

The method of claim 2, wherein the adenoplasmid accessory construct is pJM17, pBHG10 or pBHG11.

### Claim 11 (depends on 2)

The method of claim 2 further comprising the steps of:
d. applying the lysate of step (c) to a column comprising sulfonated cellulose; and
e. recovering purified replication-defective recombinant AAV virions substantially free of host cell proteins and host cell debris.

### Claim 12 (depends on 3)

The method of claim 3, wherein the heterologous gene encodes a human protein.

### Claim 13 (depends on 12)

The method of claim 12, wherein said human protein is erythropoietin, thrombopoietin (G-CSF), Factor VIII, Factor IX, Factor Xa, human growth hormone, leptin or IL-2.

### Claim 14 (depends on 3)

The method of claim 3, wherein the adenoplasmid accessory construct is pJM17, pBHG10 or pBHG11.

### Claim 15 (depends on 3)

The method of claim 3 further comprising the steps of:
d. applying the lysate of step (c) to a column comprising sulfonated cellulose; and
e. recovering purified replication-defective recombinant AAV virions substantially free of host cell proteins and host cell debris.

### Claim 16 (depends on 1)

The method of claim 1, wherein in said two AAV ITRs are wild-type.

### Claim 17 (depends on 16)

The method of claim 16, wherein said two AAV ITRs are AAV-2 ITRs.
